News | 10 December 2023
Briefs: GlaxoSmithKline Pharmaceuticals and Dr. Reddy's Laboratories
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
Demonstrate significant bleed reduction in hemophilia A and B
New facility is part of Aptar Pharma’s global expansion program
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
There has been no loss or injury to human life
Express Scripts to add Zepbound to National Preferred Formulary
NATCO temporarily shut down the operations due to cyclone with flooding/water logging of the factory premises
The company is assessing the situation and simultaneously undertaking all the requisite action
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
Venus Remedies is supplying the drug to many countries like Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana
Varenicline Tablets, 0.5 mg and 1 mg are indicated for use as an aid to smoking cessation treatment.
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
The esteemed duo perfectly embody the brand's core values of family, love, and the special bond we share with our pets
GMM Pfaudler US completes acquisition of MixPro
The acquisition will enable Cupid Limited to amplify its production capacity by 1.5 times the existing output
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Carmot Therapeutics’s R&D portfolio of clinical stage incretins has great potential to treat obesity, diabetes and potentially other diseases
Subscribe To Our Newsletter & Stay Updated
